exhibit 10. 3 certain confidential portions of this exhibit, marked by brackets, were omitted because those portions are not material and would be competitively harmful to the company if publicly disclosed. execution version license agreement this agreement is entered into with effect as of august 18, 2020 ( the “ effective date ” ) by and between f. hoffmann - la roche ltd with an office and place of business at grenzacherstrasse 124, 4070 basel, switzerland ( “ roche basel ” ) and genentech, inc. with an office and place of business at 1 dna way, south san francisco, california 94080, united states ( “ genentech ” together with roche basel “ roche ” ) on the one hand and regeneron pharmaceuticals, inc. with an office and place of business at 777 old saw mill river road, tarrytown, new york 10591, united states ( “ regeneron ” ) on the other hand. table of contents 1. definitions1. 1 accounting standards1. 2 affiliate1. 3 agreement1. 4 agreement term1. 5 alliance director1. 6 antibody1. 7 applicable law1. 8 back - up compound1. 9 barda1. 10 biosimilar product1. 11 business day1. 12 calendar quarter1. 13 calendar year1. 14 chugai asset criteria1. 15 chugai asset data package criteria1. 16 clinical study1. 17 cmo1. 18 code1. 19 co - funded development plan1. 20 co - funded studies1. 21 collaboration timepoint1. 22 combination product1. 23 commercially reasonable efforts1. 24 companion diagnostic1. 25 competitive infringement1. 26 compound1. 27 [ * * * ] 1. 28 [ * * * ] 1. 29 confidential information1. 31 control1. 32 cover1. 33 covid191. 34 cro1. 35 cta1. 36 dollars1. 37 [ * * * ] 1. 38 drug product1. 39 drug substance 1. definitions1. 1 accounting standards1. 2 affiliate1. 3 agreement1. 4 agreement term1. 5 alliance director1. 6 antibody1. 7 applicable law1. 8 back - up compound1. 9 barda1. 10 biosimilar product1. 11 business day1. 12 calendar quarter1. 13 calendar year1. 14 chugai asset criteria1. 15 chugai asset data package criteria1. 16 clinical study1